CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- 3 Insider Initial Statement of Ownership
- 424B3 Offering Prospectus
- 8-K Event Executive or director change · Other events
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 424B3 Offering Prospectus
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Regulation FD disclosure
- 4 Option exercise Director acquired 120 shares (option exercise)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 424B3 Offering Prospectus
- 8-K Event Executive or director change · Shareholder vote results
- 424B3 Offering Prospectus
- 4 Open-market sale 10% owner sold 52,529 shares at an average $15.00 ($787,981)
- ARS Other Annual Report to Security Holders
Page 9 of 14 · 268 filings